ImmuCell Q2 product sales rise 11.5% on strong US demand

ImmuCell

09/07/2026 21:19

Overview
Animal health biologics firm's preliminary Q2 product sales rose 11.5% yr/yr
Growth driven by 27.7% increase in domestic sales, while international sales declined 38.9%
Company cites robust U.S. demand and improved product availability for sales increase

Outlook
Company did not provide specific guidance for future quarters or full-year results

Result Drivers
DOMESTIC SALES SURGE - Co said 27.7% increase in domestic sales drove overall Q2 growth
PRODUCT AVAILABILITY - Management cited excellent product availability as supporting strong sales
COMMERCIAL EFFORTS - Targeting year-round, price-sensitive dairy customers and expanding commercial team contributed to growth in Dual-Force and Tri-Shield sales

Company press release: ID:nGNX1ZmM4M

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
 
$7.20 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)